fig3
![Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma](https://image.oaes.cc/3c67cdb5-50a6-4a79-9974-ba1ce2bcbfac/4467.fig.3.jpg)
Figure 3. Development of resistance to VAC treatment (decreases in EFS) in models that were intrinsically sensitive to treatment (> PR; Rh88, Rh30R, IRS-68) or models where tumors progressed through cycle 1 of VAC treatment (Rh72, Rh73). VAC: Vincristine/actinomycin-D/cyclophosphamide; EFS: event-free survival; PR: partial response.